• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    11/4/24 4:07:17 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $STRO alert in real time by email
    SC 13G/A 1 STRO_SC13GA1_2024.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (AMENDMENT NO. 1)

    SUTRO BIOPHARMA, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE
    (Title of Class of Securities)

    869367102
    (CUSIP Number)

    SEPTEMBER 30, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    2
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,296,078
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,296,078
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,296,078
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     1.6%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    3
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,031,745
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,031,745
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,031,745
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.5%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    4
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,031,745
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,031,745
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,031,745
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.5%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    5
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,031,745
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,031,745
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,031,745
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.5%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    869367102

     SCHEDULE 13G

    Page  
    6
      of   
    11
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Sutro Biopharma, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    111 Oyster Point Boulevard
    South San Francisco, California 94080

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.001 per share ("Common Stock")
     
      (e) CUSIP Number:
    869367102
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    869367102

     SCHEDULE 13G

    Page  
    7
      of   
    11
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    869367102

     SCHEDULE 13G

    Page  
    8
      of   
    11

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    9
      of   
    11

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of November 1, 2024, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    10
      of   
    11
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: November 1, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    869367102

    SCHEDULE 13G

    Page  
    11
      of   
    11
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Sutro Biopharma, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: November 1, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $STRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STRO

    DatePrice TargetRatingAnalyst
    3/17/2025Buy → Neutral
    H.C. Wainwright
    3/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$8.00 → $2.00Outperform → Neutral
    Wedbush
    3/14/2025$11.00 → $1.00Buy → Underperform
    BofA Securities
    5/8/2024$12.00Buy
    BofA Securities
    11/9/2023$12.00Buy
    Deutsche Bank
    10/6/2023$10.00Outperform
    Oppenheimer
    3/21/2023$15.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $STRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sutro Biopharma downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Sutro Biopharma from Buy to Neutral

      3/17/25 8:19:45 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma downgraded by Citizens JMP

      Citizens JMP downgraded Sutro Biopharma from Mkt Outperform to Mkt Perform

      3/14/25 7:42:27 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma downgraded by Wedbush with a new price target

      Wedbush downgraded Sutro Biopharma from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

      3/14/25 7:41:51 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

      - Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within Astellas iADC collaboration, triggering $7.5 million milestone payment to Sutro - - Cash, cash equivalents and marketable securities as of March 31, 2025 of $249.0 million, with cas

      5/8/25 4:31:42 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma to Participate in Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company's website at www.sutrobio.com. Archived replays will be available

      5/1/25 4:05:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

      SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations will cover preclinical activity and safety data for STRO-004, the Company's novel exatecan Tissue Factor ADC, as well as showcase the unique advantages of Sutro's XpressCF+® platform in enabling precise and efficient development of dual-payload ADCs. "We are excited to share our progress advancin

      4/28/25 4:05:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sutro Biopharma Inc.

      10-Q - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

      5/8/25 4:30:22 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

      5/8/25 4:28:08 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Sutro Biopharma Inc.

      DEFA14A - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

      4/25/25 4:33:08 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

      SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

      11/14/24 7:54:45 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

      SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

      11/14/24 4:30:53 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

      SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

      11/13/24 4:30:25 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO AND SECRETARY Albini Edward C converted options into 44,719 shares and covered exercise/tax liability with 15,995 shares, increasing direct ownership by 22% to 160,805 units (SEC Form 4)

      4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

      5/19/25 4:11:42 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF PEOPLE & COMM. OFFICER Fitzpatrick Linda A converted options into 37,849 shares and covered exercise/tax liability with 13,538 shares, increasing direct ownership by 25% to 119,744 units (SEC Form 4)

      4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

      5/5/25 5:48:20 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF TECH OP OFFICER Srinivasan Venkatesh converted options into 2,500 shares and covered exercise/tax liability with 894 shares, increasing direct ownership by 3% to 53,686 units (SEC Form 4)

      4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

      5/5/25 5:46:19 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $STRO
    Financials

    Live finance-specific insights

    See more

    $STRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

      – Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial resu

      3/13/25 4:07:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

      – Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 – – Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT/ 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif

      3/13/25 4:05:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

      - Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC being developed for the treatment of advanced ovarian cancer. In addition to members of the Sutro management team, the call will feature Dr. R. Wendel Naumann, Investigator in the STRO-002-GM1 stud

      12/21/22 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

      - Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - - REFRαME-O1 Part 2 (randomized portion) of the Phase 3 trial of luvelta for treatment of platinum-resistant ovarian cancer (PROC) is underway - - REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, is expected to be initiated in the second half of 2024 - - A Phase 2 trial of luvelta for the treatment of NSCLC is expected to initiate in the second half of 2024, with initial data expect

      8/13/24 4:30:00 PM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

      SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro. "We are thrilled to welcome Dr. Leyman at a pivotal time for Sutro, as we advance luvelta in two registration-directed trials in both ovarian cancer and a rare pediatric cancer and continue to leverage our proprieta

      7/9/24 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms. "Dr. Gerber's deep experience in the development of ADCs and other novel therapeutics make him an invaluable addition to our management team

      9/19/23 8:00:00 AM ET
      $STRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care